% | $
Quotes you view appear here for quick access.

Optimer Pharmaceuticals, AŞ Message Board

  • beameup_999 beameup_999 Oct 12, 2011 2:42 PM Flag

    For Your Reading Enjoyment-Independent DIFICID Survey

    NEW YORK--(BUSINESS WIRE)-- LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has published an independent survey of 62 gastroenterologists and infectious disease physicians on their current and expected use of DIFICID, a newly commercialized antibiotic for the treatment of Clostridium difficile-associated diarrhea (CDAD) from Optimer Pharmaceuticals, Inc. (NasdaqGM:OPTR - News).

    “We believe these results communicate important insights into the launch of this new product,” said Andrew I. McDonald, Ph.D., Managing Director at LifeSci Advisors. “Awareness of DIFICID is high, at 85% of responders, and almost 20% intend to use the drug first line and 60% intend to use after FLAGYL failure. Ultimately, the survey responders indicated that they intend to treat 20% of their total CDAD patient population with DIFICID in 12 months.”

    My Comments:

    With 700,000 cases in the US alone this year, 20% times $2000 a treatment package results in $280,000,000 of sales. This is very encouraging. It will be instructive to see the latest sales figures (probably as part of their earnings report at the end of October).

    SortNewest  |  Oldest  |  Most Replied Expand all replies